Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor
Metabolic activity and hypoxia are both important factors characterizing tumor aggressiveness. Here, we used F-18 fluoromisonidazole (FMISO) and F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) to define metabolically active hypoxic volume, and investigate its clinical significance in relation to progression free survival (PFS) and overall survival (OS) in glioblastoma patients.
Glioblastoma patients (n = 32) underwent FMISO PET, FDG PET, and magnetic resonance imaging (MRI) before surgical intervention. FDG and FMISO PET images were coregistered with gadolinium-enhanced T1-weighted MR images. Volume of interest (VOI) of gross tumor volume (GTV) was manually created to enclose the entire gadolinium-positive areas. The FMISO tumor-to-normal region ratio (TNR) and FDG TNR were calculated in a voxel-by-voxel manner. For calculating TNR, standardized uptake value (SUV) was divided by averaged SUV of normal references. Contralateral frontal and parietal cortices were used as the reference region for FDG, whereas the cerebellar cortex was used as the reference region for FMISO. FDG-positive was defined as the FDG TNR ≥1.0, and FMISO-positive was defined as FMISO TNR ≥1.3. Hypoxia volume (HV) was defined as the volume of FMISO-positive and metabolic tumor volume in hypoxia (hMTV) was the volume of FMISO/FDG double-positive. The total lesion glycolysis in hypoxia (hTLG) was hMTV × FDG SUVmean. The extent of resection (EOR) involving cytoreduction surgery was volumetric change based on planimetry methods using MRI. These factors were tested for correlation with patient prognosis.
All tumor lesions were FMISO-positive and FDG-positive. Univariate analysis indicated that hMTV, hTLG, and EOR were significantly correlated with PFS (p = 0.007, p = 0.04, and p = 0.01, respectively) and that hMTV, hTLG, and EOR were also significantly correlated with OS (p = 0.0028, p = 0.037, and p = 0.014, respectively). In contrast, none of FDG TNR, FMISO TNR, GTV, HV, patients’ age, or Karnofsky performance scale (KPS) was significantly correlated with PSF or OS. The hMTV and hTLG were found to be independent factors affecting PFS and OS on multivariate analysis.
We introduced hMTV and hTLG using FDG and FMISO PET to define metabolically active hypoxic volume. Univariate and multivariate analyses demonstrated that both hMTV and hTLG are significant predictors for PFS and OS in glioblastoma patients.
KeywordsAnaerobic glycolysis Glioblastoma Fluoromisonidazole Fluorodeoxyglucose Positron emission tomography
- 5.Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H, et al. 18F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging. 2012;39(5):760–70. doi:10.1007/s00259-011-2037-0.
- 8.Toyonaga T, Hirata K, Yamaguchi S, Hatanaka KC, Yuzawa S, Manabe O, et al. 18F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors. Eur J Nucl Med Mol Imaging. 2016. doi:10.1007/s00259-016-3320-x.
- 9.Bell C, Dowson N, Fay M, Thomas P, Puttick S, Gal Y, et al. Hypoxia imaging in gliomas with 18F-fluoromisonidazole PET: toward clinical translation. Semin Nucl Med. 2015;45(2):136–50. doi:10.1053/j.semnuclmed.2014.10.001.
- 11.Spence AM, Muzi M, Swanson KR, O’Sullivan F, Rockhill JK, Rajendran JG, et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res: Off J Am Assoc Cancer Res. 2008;14(9):2623–30. doi:10.1158/1078-0432.CCR-07-4995.
- 12.Swanson KR, Chakraborty G, Wang CH, Rockne R, Harpold HL, Muzi M, et al. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med: Off Publ Soc Nucl Med. 2009;50(1):36–44. doi:10.2967/jnumed.108.055467.
- 13.Szeto MD, Chakraborty G, Hadley J, et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res. 2009;69(10):4502–9. doi:10.1158/0008-5472.CAN-08-3884.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Kawai N, Lin W, Cao WD, Ogawa D, Miyake K, Haba R, et al. Correlation between 18F-fluoromisonidazole PET and expression of HIF-1alpha and VEGF in newly diagnosed and recurrent malignant gliomas. Eur J Nucl Med Mol Imaging. 2014;41(10):1870–8. doi:10.1007/s00259-014-2776-9.
- 16.Spence AM, Muzi M, Graham MM, O’Sullivan F, Link JM, Lewellen TK, et al. 2-[18F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome. Clin Cancer Res: Off J Am Assoc Cancer Res. 2002;8(4):971–9.Google Scholar
- 18.Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Human Brain Mapp. 1994;2(4):189–210. doi:10.1002/hbm.460020402.
- 19.Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J Nucl Med: Off Publ Soc Nucl Med. 2004;45(11):1851–9.Google Scholar
- 21.Yamaguchi S, Kobayashi H, Hirata K, Shiga T, Tanaka S, Murata J, et al. Detection of histological anaplasia in gliomas with oligodendroglial components using positron emission tomography with 18F-FDG and 11C-methionine: report of two cases. J Neuro-Oncol. 2011;101(2):335–41. doi:10.1007/s11060-010-0262-1.
- 22.Kobayashi K, Hirata K, Yamaguchi S, Manabe O, Terasaka S, Kobayashi H, et al. Prognostic value of volume-based measurements on 11C-methionine PET in glioma patients. Eur J Nucl Med Mol Imaging. 2015;42(7):1071–80. doi:10.1007/s00259-015-3046-1.
- 23.Yoshikawa K, Kajiwara K, Morioka J, et al. Improvement of functional outcome after radical surgery in glioblastoma patients: the efficacy of a navigation-guided fence-post procedure and neurophysiological monitoring. J Neuro-Oncol. 2006;78(1):91–7. doi:10.1007/s11060-005-9064-2.CrossRefGoogle Scholar
- 25.Therneau T. A package for survival analysis in S. version 2.38. 2015. http://CRAN.R-project.org/package=survival. Accessed 25 Sept 2016.
- 26.Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):3–8. doi:10.3171/2011.2.JNS10998.
- 32.Marko NF, Weil RJ, Schroeder JL, Lang FF, Suki D, Sawaya RE. Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol : Off J Am Soc Clin Oncol. 2014;32(8):774–82. doi:10.1200/JCO.2013.51.8886.CrossRefGoogle Scholar
- 36.Suzuki H, Nishio M, Nakanishi H, Hanai N, Hirakawa H, Kodaira T, et al. Impact of total lesion glycolysis measured by 18F-FDG-PET/CT on overall survival and distant metastasis in hypopharyngeal cancer. Oncol Lett. 2016;12(2):1493–500. doi:10.3892/ol.2016.4765.
- 38.Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S, et al. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med : Off Publ Soc Nucl Med. 2012;53(10):1506–13. doi:10.2967/jnumed.111.101402.
- 39.Moon SH, Choi JY, Lee HJ, Son YI, Baek CH, Ahn YC, et al. Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters. Head Neck. 2013;35(1):15–22. doi:10.1002/hed.22904.
- 40.Picchio M, Kirienko M, Mapelli P, Dell’Oca I, Villa E, Gallivanone F, et al. Predictive value of pre-therapy 18F-FDG PET/CT for the outcome of 18F-FDG PET-guided radiotherapy in patients with head and neck cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):21–31. doi:10.1007/s00259-013-2528-2.
- 44.Yasuda K, Onimaru R, Okamoto S, Shiga T, Katoh N, Tsuchiya K, et al. [18F]fluoromisonidazole and a new PET system with semiconductor detectors and a depth of interaction system for intensity modulated radiation therapy for nasopharyngeal cancer. Int J Radiat Oncol Biol Phys. 2013;85(1):142–7. doi:10.1016/j.ijrobp.2012.03.029.